Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909343 | 0.88 | JAK2 (0.33) | JAK2JAK1PDK2 | |
| SCHEMBL22891633 | 0.85 | MEN1 (0.40) | EPHX2CYP2C9JAK2JAK1PDK2 | |
| SCHEMBL18909240 | 0.81 | EPHX2 (0.41) | EPHX2NPY5RCYP2C9 | |
| SCHEMBL17285910 | 0.77 | KMT2A (0.42) | — | |
| SCHEMBL18909336 | 0.77 | EPHX2 (0.39) | EPHX2NPY5RPGRCYP2D6CYP2C9 | |
| SCHEMBL18673325 | 0.76 | KMT2A (0.31) | — | |
| SCHEMBL22891231 | 0.74 | EPHX2 (0.49) | EPHX2EPHX1 | |
| SCHEMBL19275282 | 0.74 | EPHX2 (0.44) | EPHX2NPY5REPHX1 | |
| SCHEMBL21281068 | 0.74 | NPY5R (0.38) | EPHX2NPY5RPGRCYP2D6CYP2C9 | |
| SCHEMBL21500975 | 0.74 | HRH3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-3596072-B1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-06-22 | — | — | EP | disclosed |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200165260-A1 | INHALED POWDER FORMULATIONS | GENENTECH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | EPHX2 1730/4885NPY5R 2990/4885PGR 1368/4885 |
| US-20200165260-A1 | INHALED POWDER FORMULATIONS | JAK1, STAT5A, JAK2 | EPHX2 4091/4885NPY5R 394/4885PGR 1084/4885 |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | EPHX2 1730/4885NPY5R 2990/4885PGR 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.